Endocrine-focused biopharmaceutical company developing novel long-acting recombinant human growth hormone for growth hormone deficiency
Location: United States, California, Redwood City
Total raised: $121M
Investors 6
| Date | Name | Website |
| - | Aisling Ca... | aislingcap... |
| - | RA Capital... | racap.com |
| - | Sofinnova ... | sofinnova.... |
| - | Perceptive... | perceptive... |
| - | Advent Lif... | adventls.c... |
| - | New Leaf V... | nlvpartner... |
Funding Rounds 4
| Date | Series | Amount | Investors |
| 19.02.2014 | Series E | $55M | - |
| 08.10.2013 | Series D | $20M | - |
| 15.01.2013 | Series C | $25M | - |
| 17.02.2011 | Series B | $21M | - |
Mentions in press and media 15
| Date | Title | Description |
| 25.10.2022 | Aravive Announces Approximately $41.5 Million Private Placement Financing | HOUSTON, Oct. 25, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV) (“Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, announced that it has entered into definitive agreemen... |
| 25.10.2022 | Aravive Announces Approximately $41.5 Million Private Placement Financing | Priced At-The-Market with Substantial Participation from both New Life Sciences Specialist Investors as well as Large Existing Investors /EIN News/ -- HOUSTON, Oct. 25, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV) (“Company”), a la... |
| 29.06.2016 | The biotech IPO feast flags as investors lose their appetite for R&D risk | There was a time after the 2008 crash that biotech IPOs were about as popular as snow in March. But from 2013 through 2015 generalist investors got over their fears and jumped into one of the hottest stock games on the planet. Fund... |
| 19.02.2014 | Cash-flush Versartis swings for an $80M IPO to advance its orphan drug | On the same day it announced a $55 million E round, California biotech Versartis filed to go public in an $80 million IPO, planning to use its fast-growing bank account to get a promising orphan therapy through late-stage trials. With the c... |
| 19.02.2014 | Versartis Completes $55M Series E Financing | Versartis, Inc., a Redwood City, CA-based endocrine-focused biopharmaceutical company, completed a $55m Series E financing. Five undisclosed new investors (life science investment firms) joined existing investors Sofinnova Ventures, Aisling... |
| 18.02.2014 | Versartis Secures $55M in Series E | REDWOOD CITY, CA, Endocrine-focused biopharmaceutical company today announced that it has completed a $55 million Series E financing. >> Click here for more funding data on Versartis >> To export Versartis funding data to PD... |
| 08.10.2013 | Versartis nabs $20M in VC cash to take growth hormone to PhIII | California's Versartis is having quite a year, pulling down another $20 million in venture financing to get its once-a-month growth hormone through mid-stage trials. The latest haul brings new investor Sofinnova Ventures to the table, joini... |
| 08.10.2013 | Versartis Completes $20M Series D Financing | Versartis, Inc., a Redwood City, CA-based biotechnology company developing novel therapeutics for patients with endocrine disorders, completed a $20m Series D financing. The round was led by new investor Sofinnova Ventures, with participati... |
| 29.01.2013 | Once-monthly HGH replacement therapy gets $25 million VC boost for pediatric trial | Versartis uses technology called XTEN to extend the half-life of proteins. It thinks compounds it develops using XTEN technology could provide more stable and convenient therapies with enhanced efficacy and fewer side effects. Its lead prod... |
| 15.01.2013 | Versartis Completes $25M Series C Financing | Versartis, Inc., a Redwood City, CA-based biotechnology company developing novel therapeutics for patients with endocrine disorders, completes a $25m Series C financing. The round was led by new investor Aisling Capital with participation f... |
Show more